99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight
Place of Origin | China |
---|---|
Brand Name | XRD |
Certification | GMP |
Model Number | 96829-58-2 |
Minimum Order Quantity | negotiable |
Price | Inquiry for Negotiable |
Packaging Details | 1-2 kg / aluminum foil bag, 25kg/ drum, as required |
Delivery Time | 1-2days after payment received |
Payment Terms | T/T bank, Western Union, Bitcoin, Etc |
Supply Ability | 1000KG/ Month |

Contact me for free samples and coupons.
Whatsapp:0086 18588475571
Wechat: 0086 18588475571
Skype: sales10@aixton.com
If you have any concern, we provide 24-hour online help.
xCAS | 96829-58-2 | Product Name | Orlistat |
---|---|---|---|
Type | Pharmaceutical Raw Material | Appearance | White Powder |
Usage | For Loss Weight | Alias | Orlipastat ,XENICAL |
Assay | 99% | Key Words | Orlistat |
High Light | pharm raw material,research chemicals |
99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight
1. Basic Info
Product Name: | Orlistat |
Synonyms: | (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER;RO-18-0647;XENICAL;(-)-TETRAHYDROLIPSTATIN;ORLISTAT;N-FORMYL-L-LEUCINE (1S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]DODECYL ESTER;(-)-Tetrahydrolipstatin(EquivalentToOrlistat);Orlipastat |
CAS: | 96829-58-2 |
MF: | C29H53NO5 |
MW: | 495.73 |
EINECS: | 639-755-1 |
Product Categories: | Pharmaceutical Raw Materials;Miscellaneous Biochemicals;API;Antiobesity Agent;Chiral Reagents;Intermediates & Fine Chemicals;-;Pharmaceuticals;Amino Acids & Derivatives;Heterocycles;ACTOS;Other APIs;Lipid-lowering medicine reducing weight |
Mol File: | 96829-58-2.mol |
![]() |
2. Descriptions:
Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name by Roche in most countries, and is sold over-the-counter as by GlaxoSmithKline in the United Kingdom and the United States.Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini.However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug.
3. Applications:
Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat. After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost.
The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%). Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).
Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. The effectiveness of orlistat in promoting weight loss is definite, Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.
The effectiveness of orlistat in promoting weight loss is clear, albeit moderately. The pooled data from clinical trials show that people who give olivide have less than 2-3 kilograms (4.4-6.6 pounds) of medication than a year, except for changes in lifestyle such as diet and exercise. Is also a modest reduction in blood pressure, it seems to be able to prevent the onset of type 2 diabetes, whether due to weight loss itself or other effects; in a large randomized controlled trial, orlistat he was found in obese people will reduce the incidence of diabetes by nearly 40%
Orlistat is used for the treatment of obesity. The amount of weight loss achieved with orlistat varies. In one-year clinical trials, between 35.5% and 54.8% of subjects achieved a 5% or greater decrease in body mass, although not all of this mass was necessarily fat. Between 16.4% and 24.8% achieved at least a 10% decrease in body fat.After orlistat was stopped, a significant number of subjects regained weight-up to 35% of the weight they had lost. The incidence of type 2 diabetes in an obese population over four years is decreased with orlistat (6.2%) compared to placebo (9.0%).Long-term use of orlistat also leads to a modest reduction in blood pressure (mean reductions of 2.5 and 1.9 mmHg in systolic and diastolic blood pressure respectively).
4. Orlistat COA
tems | Specification Items | Result |
Appearance | white or almost white crystalline powder,smell less | White crystalline powder |
Melting Point | 42.0~46.0°C | Confirmed |
Specific Rotation | -31°~-39°(CHCl3,C=1) | Confirmed |
Identification | The result of HPLC is consisitent to the reference one. The result of IR is consisitent to the reference one. | Confirmed |
Related Substances | ≤ 0.5% | ≤ 0.05% |
Total impurity | ≤ 1.0% | Confirmed |
Single impurity | ≤ 0.1% | Confirmed |
≤ 290ppm | Confirmed | |
≤ 5000ppm | Confirmed | |
Residual on Ignition | ≤0.1% | Confirmed |
Sulphate | ≤ 0.05% | Confirmed |
Heavy Metal | ≤ 20ppm | Confirmed |
Purity | ≤ 99.0% ~ 99.9% | Confirmed |
99%min USP/EP Orlistat Manufacturer CAS 96829-58-2 For Loss Weight